At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 180 enrolled
Drug / intervention
CM310 +1 morebiological
Likely dose
CM310 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis
In Brief
A Phase 3 clinical trial evaluating CM310 and Placebo for Chronic Rhinosinusitis With Nasal Polyposis. Completed, enrolled 180 participants across 1 site.
Detailed Summary
This is a multi-center, randomized, double blind, placebo-controlled Phase III study to evaluate the efficacy and safety of CM310, and to observe the life quality of subjects, the Pharmacokinetics, Pharmacodynamics and immumogenicity of CM310 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartAug 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedJun 29, 2022
Enrollment StartAug 9, 2022
Primary CompletionJun 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.0 years ago
Interventions
CM310biological
300 mg every two weeks
Placebobiological
once every two weeks